SS-31 (Elamipretide) · Research brief
SS-31 Elamipretide Stability and Degradation Explained
Short answer
SS-31 elamipretide stability degradation behaviour is governed by which of two physical states the material is in. As a sealed, cold, dark, dry lyophilized solid, this tetrapeptide is comparatively durable, and the solid-state peptide literature indicates that residual water content, storage temperature and light exposure are the variables that matter most.
SS-31 elamipretide stability degradation behaviour is governed by which of two physical states the material is in. As a sealed, cold, dark, dry lyophilized solid, this tetrapeptide is comparatively durable, and the solid-state peptide literature indicates that residual water content, storage temperature and light exposure are the variables that matter most. Once the same material is in aqueous solution, the chemical features that make it interesting become the features most likely to change: an electron-rich 2',6'-dimethyltyrosine ring that is readily oxidized, a C-terminal carboxamide that can hydrolyze, a short backbone that can cyclize at the N-terminus, and a strongly cationic character that encourages adsorption to container surfaces at low concentrations. Temperature, oxygen, light, trace transition metals, pH and repeated freeze-thaw cycles each accelerate one or more of those routes. The practical consequence for a research laboratory is that stability is not a property of the compound in the abstract, it is a property of a specific lot held under specific conditions, confirmed by analysis rather than assumed.
What is SS-31 and why does its structure determine how it degrades?
SS-31, also known as elamipretide and as MTP-131, is a synthetic, water-soluble tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine and the C-terminus is an amide rather than a free acid. It is commonly listed under CAS 736992-21-5 with the molecular formula C32H49N9O5 and a free-base molecular weight near 640, and Real Peptides supplies it as a research-use-only catalog compound at SS-31 (elamipretide) with a broader compound overview at the SS-31 page.
The structure predicts the degradation map. There is no cysteine, so disulfide scrambling and thiol oxidation are not available pathways. There is no methionine, so the classic sulfoxide route that dominates many peptide stability discussions does not apply. There is no asparagine or glutamine, so the succinimide-mediated deamidation and isomerization chemistry described in Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides (J Biol Chem, 1987) is not directly relevant here, although that paper remains the standard reference for why residue identity, not peptide length, sets the dominant decay route. What the molecule does have is a phenol ring flanked by two methyl groups, a second aromatic ring at the C-terminal phenylalanine, a guanidinium group, a lysine side-chain amine and a terminal carboxamide.
Alternating aromatic and cationic residues give the peptide a net positive charge at neutral pH, which is central to its described interaction with the anionic phospholipid cardiolipin and which also means the molecule binds readily to negatively charged glass and some plastics. The D-configuration arginine at position one slows aminopeptidase cleavage in biological matrices but confers no protection against purely chemical hydrolysis or oxidation. Structural reasoning of this kind predicts which pathways are available; it does not establish rates, and no researcher should treat a predicted pathway as a measured shelf life.
How stable is SS-31 as a lyophilized powder?
The lyophilized solid is by a wide margin the most stable form, and cold, dry, dark, sealed storage is what the solid-state literature supports. In an amorphous glassy solid, molecular mobility is low, reactant diffusion is restricted, and most degradation chemistry slows by orders of magnitude relative to solution. Lyophilization and development of solid protein pharmaceuticals (Int J Pharm, 2000) reviews this in detail and reports that residual moisture content, the glass transition temperature of the amorphous matrix and the storage temperature relative to that transition are the principal determinants of solid-state degradation rate. Water in a freeze-dried cake acts both as a chemical reactant and as a plasticizer that increases mobility, which is why dryness and cold reinforce each other rather than acting independently.
In practice, laboratories hold lyophilized research peptides at minus 20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for shorter working periods, with ambient-temperature transit treated as an acceptable excursion for dry solids rather than as a failure. The limit on that general statement is important: the review cited above is built mainly on protein formulations, and extrapolating glass-transition arguments from a lyophilized protein cake to a small, highly soluble tetrapeptide salt is inexact. A tetrapeptide does not unfold, aggregate or lose tertiary structure, so several of the failure modes that dominate protein lyophilization are simply absent.
Two physical observations recur with small peptide fills. First, acetate salts of basic peptides are hygroscopic, so a cold vial opened into humid room air can condense moisture onto the solid and raise its water content, which is why equilibration of sealed vials to room temperature before unsealing is standard laboratory practice. Second, small fill quantities often present as a thin translucent film or a scattering of material on the vial wall rather than a visible cake; that appearance reflects the lyophilization cycle and fill mass, not degradation. Discoloration, a collapsed or shrunken cake, or visible moisture are the appearance changes that warrant analytical follow-up.
How long does SS-31 remain intact once it is in solution?
Once dissolved, stability becomes far shorter and far less predictable, and the honest answer is that a laboratory determines the usable hold time for its own solution with its own stability-indicating assay rather than reading it from a general table. In water, every degradation route that was suppressed in the glassy solid becomes available: hydrolysis of the C-terminal amide and of backbone bonds, oxidation driven by dissolved oxygen and trace metals, base-catalyzed cyclization and epimerization, microbial growth in unpreserved aqueous media, and physical loss to container surfaces.
Instability, stabilization, and formulation of liquid protein pharmaceuticals (Int J Pharm, 1999) remains the broad map of these solution pathways and reports that temperature, pH, ionic strength, oxygen, light and surface contact interact rather than acting as independent variables. Stability of protein pharmaceuticals: an update (Pharm Res, 2010) revisits the same chemistry with later analytical methods and reports that chemical and physical instability frequently proceed in parallel, so a single analytical readout can understate total change. Both are reviews of protein and peptide pharmaceuticals in general; neither reports kinetics for this specific tetrapeptide, and neither should be read as supplying a shelf life for any particular solution.
What follows from that literature for a short cationic peptide is a set of expectations rather than numbers. Cold storage suppresses hydrolysis and oxidation. Protection from light suppresses photochemically initiated radical chemistry at the aromatic residues. Limiting headspace oxygen and avoiding metal contamination suppress oxidative routes. Dividing a stock into single-use portions avoids the repeated warming and refreezing that drives cumulative loss. At low concentrations, adsorption can remove a meaningful fraction of the peptide from solution without producing any new chromatographic peak at all, which is why mass balance, not just peak purity, is the more informative measurement when a laboratory sees declining activity with an apparently clean chromatogram.
Which degradation pathways matter most for this peptide?
For SS-31 the pathways worth monitoring, in rough order of likelihood, are oxidation of the dimethyltyrosine ring, hydrolysis of the C-terminal carboxamide, cyclization or cleavage at the N-terminal dipeptide, epimerization under basic conditions, and non-chemical loss by surface adsorption.
Oxidation of an electron-rich phenol proceeds through a phenoxyl radical intermediate and can give hydroxylated species, quinone-type products and dimeric crosslinks. The diagnostic signature in mass spectrometry is a shift of about plus 16 mass units for a single oxygen addition, with plus 32 for a second, and a dimer mass for crosslinked material. Visible yellowing of a solution is a coarse but real warning sign for phenolic oxidation.
Hydrolysis of the C-terminal amide converts the carboxamide to a free carboxylic acid, a change of roughly plus 1 mass unit that is readily resolved by high-resolution mass spectrometry but easily missed by low-resolution instruments and sometimes poorly separated by a short reversed-phase gradient. The change alters the peptide's net charge and can alter its interaction with anionic membranes.
Diketopiperazine formation, in which the first two residues cyclize and leave the peptide, is a recognized route for short peptides with a flexible N-terminus and is generally favoured at neutral to mildly alkaline pH and elevated temperature. The result is a truncated dipeptide plus a cyclic byproduct, both of which appear as new low-mass species.
Epimerization at the alpha carbon is base-catalyzed and would convert a defined stereocentre into a diastereomeric impurity with the same mass. Because the mass is unchanged, only chiral analysis or a chromatographic method that resolves diastereomers will detect it. Finally, adsorption is not degradation but behaves like it in an assay, lowering effective concentration without generating a degradant peak.
Why is the dimethyltyrosine residue the main oxidation risk?
The same phenol that gives the molecule its described radical-scavenging chemistry is also the easiest site in the peptide to oxidize, and that is not a coincidence. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury (J Biol Chem, 2004) introduced this family of aromatic-cationic peptides and reports that members carrying a tyrosine or dimethyltyrosine residue scavenge reactive oxygen species, reduce lipid peroxidation, and limit mitochondrial swelling and oxidative cell death in cell-based and ex vivo reperfusion models. The two ortho methyl groups on the ring increase electron density and thereby increase the ease with which the phenol donates a hydrogen atom to a radical. A molecule designed to be a good hydrogen donor in a biological setting is, by the same chemistry, a good hydrogen donor to atmospheric oxygen and to metal-catalyzed oxidants in a storage vial.
The mechanistic implication is that oxidative stress applied in storage consumes the structural feature responsible for the compound's described antioxidant behaviour. The peptide chemistry literature describes a general sequence for phenolic oxidation: radical abstraction, formation of hydroxylated products, and in some conditions dimerization through carbon-carbon coupling between two rings. Each of those products is detectable by mass, and the hydroxylated species are usually separable by a sufficiently shallow reversed-phase gradient.
The limits of this reasoning should be stated plainly. The 2004 paper is a mechanism and bioactivity study, not a stability study; it characterizes what the intact peptide does to radicals, not what radicals do to the peptide during storage. It does not publish degradant profiles, forced-degradation data or rate constants, and nothing in it quantifies how much oxidation a given storage condition produces. What it supports is the qualitative inference that the dimethyltyrosine residue is chemically reactive toward oxidants, which in turn supports treating oxygen exposure, trace metal contamination and light as the conditions most worth controlling.
Does light exposure degrade SS-31?
Light is a credible degradation stressor for this peptide because both aromatic residues absorb in the ultraviolet range, and dark storage is the standard precaution. Phenylalanine and tyrosine-type chromophores absorb near 260 to 280 nanometres, and absorbed energy can initiate radical chemistry directly or through photosensitized production of reactive oxygen species in the surrounding solution. Photo-oxidation of phenolic side chains is described throughout the peptide chemistry literature as a route to hydroxylated and crosslinked products, which are the same families of degradant produced by thermal and metal-catalyzed oxidation, reached by a different initiation step.
Practical handling in laboratories reflects this: amber glass, foil-wrapped vials, closed freezers and benchwork performed away from direct sunlight or unfiltered UV sources. Dry solids are less photolabile than solutions because the reaction partners, dissolved oxygen and mobile water, are largely absent, but photostability of the solid should not be assumed to be absolute.
The regulatory framework for testing this is ICH Q1B, which describes how photostability studies on drug substances are structured, including exposure to defined visible and ultraviolet energy and the use of protected control samples run alongside the exposed samples. That document describes a method framework rather than results for any particular compound. No published photostability dataset specific to this tetrapeptide is available to cite here, so the honest position is that the pathway is chemically plausible and well precedented for aromatic peptides, the mitigation is inexpensive, and a laboratory that needs a number generates it by exposing a sample and running a stability-indicating method against a dark control. Anyone reporting a light-sensitivity claim without that control is describing an expectation, not a measurement.
How do temperature excursions and freeze-thaw cycles affect the peptide?
Repeated freeze-thaw cycling is one of the most common and most avoidable stressors applied to peptide solutions, and single-use portions are the standard mitigation. The mechanism is not simply cold damage. When an aqueous solution freezes, pure ice forms first and the remaining liquid becomes a progressively concentrated phase containing the peptide, the buffer salts and any trace metals or oxidants present. That cryoconcentrated phase can reach solute concentrations far above the nominal value, and in some buffer systems one component crystallizes before the other, shifting the pH of the unfrozen phase substantially during the freezing process. Large ice-liquid interfaces also provide surface area for adsorption.
Instability, stabilization, and formulation of liquid protein pharmaceuticals (Int J Pharm, 1999) and Stability of protein pharmaceuticals: an update (Pharm Res, 2010) both report freeze-thaw stress and buffer-dependent pH shift on freezing as established contributors to loss, and both describe aliquoting and buffer selection as the usual controls. The limit on applying those reviews here is again model mismatch: most of the freeze-thaw damage they describe is aggregation and conformational loss in proteins, which a four-residue peptide cannot undergo. For SS-31 the plausible freeze-thaw consequences are chemical, through transient pH and concentration extremes, and physical, through adsorption and incomplete redissolution after thawing.
Warm excursions act through a simpler mechanism. Reaction rates rise with temperature across all the chemical pathways described above, so an excursion contributes cumulative degradation in proportion to both its magnitude and its duration. A dry solid at ambient temperature for a transit period and a solution at ambient temperature for the same period are not comparable exposures. Laboratories that need defensible numbers log storage temperature, record the number of thaw events per container and re-test a retained sample rather than relying on recollection of how a vial has been handled. Real Peptides publishes its location and shipping details at the location page, which is the relevant information for estimating transit exposure.
How do pH, buffer composition and trace metals change the picture?
pH determines which degradation route dominates, which is why a solution described only by its concentration is under-specified from a stability standpoint. Under mildly acidic conditions the phenol is fully protonated and the lysine and arginine side chains are charged, which suppresses the phenolate-mediated oxidation chemistry and the base-catalyzed routes to epimerization and diketopiperazine formation. Under neutral to alkaline conditions the reverse is true: deprotonation of the phenol makes the ring substantially easier to oxidize, and base catalysis accelerates both cyclization at the N-terminus and racemization at alpha carbons. Strongly acidic conditions combined with heat favour amide and backbone hydrolysis instead. There is therefore no single pH that is optimal for every pathway, only a pH that trades one risk against another.
Trace transition metals deserve separate attention because they are often present unintentionally, leached from glass, introduced with buffer salts, or carried in from upstream handling. Iron and copper in trace quantities catalyze Fenton-type chemistry that converts dissolved oxygen and peroxide contaminants into hydroxyl radicals, and those radicals attack electron-rich aromatic rings preferentially. Formulation research routinely addresses this with metal chelators, and the reviews cited above report chelation and oxygen exclusion as general stabilizing strategies for oxidation-sensitive peptides.
The limits here are real. These are general principles from peptide and protein formulation science, and they describe tendencies rather than a validated condition set for this compound. No published buffer-by-buffer stability matrix for SS-31 is available to cite. A laboratory that needs to know how its own buffer performs establishes that empirically by holding samples under its real conditions and analyzing them at intervals against a frozen reference. Real Peptides supplies the compound for exactly that kind of work and does not supply preparation guidance, because these are research-use-only materials.
What role do the counterion, residual water and hygroscopicity play?
The counterion and the water content of a lyophilized peptide affect both its stability and the accuracy of any concentration calculation, and both are routinely under-appreciated. Basic peptides are isolated as salts, most often acetate or trifluoroacetate, depending on the final purification and lyophilization steps. The counterion is part of the mass in the vial. A vial labelled with a given mass of salt-form material does not contain that same mass of free-base peptide, and where a certificate of analysis reports net peptide content separately from gross mass, the net figure is the one that concentration arithmetic uses.
Residual trifluoroacetate has a second, assay-level consequence that is well known in cell biology: it can affect sensitive cell-based readouts independently of the peptide, which is why some laboratories specify acetate-form material or an additional ion-exchange step for cell work. Residual water matters for a different reason. Karl Fischer titration quantifies it, and the solid-state review cited above reports that water content governs mobility and reaction rate in an amorphous solid. A hygroscopic acetate salt that has absorbed atmospheric moisture is no longer the material described on its certificate.
This is also where the only measurement education appropriate to a research-use-only page belongs, and it stops at the concentration framework. Concentration is mass divided by volume: a nominal 10 mg of material taken up in 10 mL of solvent gives a nominal 1 mg per mL stock, and the word nominal is doing work in that sentence because gross mass, net peptide content and residual water all sit between the label and the true concentration.
Which analytical methods detect degradation in a peptide like this?
The core combination is reversed-phase HPLC with ultraviolet detection for purity and orthogonal mass spectrometry for identity and degradant mass, supported by water content, counterion and chiral analyses when the question demands them. Reversed-phase separation of a small cationic peptide is usually performed on a C18 column with an acidic ion-pairing mobile phase, with detection at 214 nanometres for the amide bond and at 280 nanometres for the aromatic residues. Running both wavelengths is informative: a peak that responds at 214 but not at 280 is unlikely to contain an intact aromatic chromophore, which is a useful signal when truncation is suspected.
Mass spectrometry supplies the identity confirmation and the degradant map. Electrospray high-resolution mass spectrometry resolves the roughly plus 1 mass unit shift of amide hydrolysis, which low-resolution instruments cannot reliably distinguish from isotopic signal, and resolves plus 16 and plus 32 oxidation products cleanly. Tandem fragmentation locates where a modification sits within the sequence rather than merely confirming that one exists. MALDI time-of-flight analysis is a fast identity check but is less suited to quantifying small mass shifts.
Several changes are invisible to the core methods. Epimerization produces an isobaric species, so it requires chiral analysis following hydrolysis or a chromatographic method validated to separate diastereomers. Adsorptive loss produces no new peak at all and is detected by quantitative recovery against an external standard. Co-elution is the quiet failure mode of any single gradient, so forced degradation studies, conducted under the framework described in ICH Q1A(R2), are how a laboratory demonstrates that its method actually separates the degradants it is supposed to detect. Those studies deliberately stress samples with acid, base, oxidant, heat and light, then confirm that the resulting species resolve from the parent peak. A method that has never been challenged that way is a purity method, not a stability-indicating method.
What does a certificate of analysis actually tell a researcher about stability?
A certificate of analysis documents identity and purity for a specific lot, measured by stated methods on a stated date, and that is both more and less than a stability guarantee. It is more, because it anchors every later measurement to a defined starting point: a chromatogram, a mass spectrum, a lot number and a test date together let a laboratory distinguish a material that arrived out of specification from a material that changed afterward. It is less, because no certificate can describe what happened to the vial in transit, in a shared freezer, or across a year of intermittent use.
Real Peptides publishes independent third-party certificates of analysis for every batch, and those documents are publicly available at the COA library. The verification steps that precede procurement are straightforward and apply to any supplier: confirm that the CAS number and molecular formula on the documentation match the compound intended, confirm that the reported mass matches the expected molecular weight for the stated salt form, confirm that the lot number on the vial matches the lot number on the certificate, and confirm that the analytical methods listed are capable of answering the question being asked. A mass spectrum alone confirms identity but says nothing about chromatographic purity; a chromatogram alone confirms homogeneity under one condition but does not confirm which molecule produced the peak.
The stability-relevant reading of a certificate is therefore comparative. The chromatogram on the certificate is the reference trace. A laboratory that runs the same method on the same lot after six months of storage and overlays the two traces has generated real stability information for its own conditions. That comparison is the only way to convert a point-in-time document into a stability record, and it is the reason retained reference samples held under the coldest available condition are worth the freezer space.
How does degraded material change experimental results?
Degradation affects results through two separate mechanisms, loss of active material and introduction of species that behave differently, and the two are frequently mistaken for one another. The published mechanism of SS-31 makes the first mechanism easy to reason about. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin (J Am Soc Nephrol, 2013) reports that the peptide associates with cardiolipin in the inner mitochondrial membrane and that this interaction underlies its reported effects on mitochondrial function in ischemic models. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics (Br J Pharmacol, 2014) reviews that mechanism across models and frames the aromatic-cationic motif as central to the interaction.
If the alternating charge and aromatic pattern is what drives membrane association, then truncation at the N-terminus removes both the guanidinium group and the phenol ring in a single event, and oxidation of the phenol alters the ring that the 2004 study implicates in radical scavenging. The reasonable inference is that degradants are unlikely to behave identically to intact peptide, and the honest qualifier is that published structure-activity data on these specific degradants is limited, so their behaviour should be treated as unknown rather than as inactive.
The quieter problem is concentration error. A stock that has lost material to container walls, or whose label mass included more counterion and water than assumed, delivers less peptide than the experimental record states. The visible symptoms are a rightward shift in concentration-response curves, poor agreement between replicate preparations, and apparent loss of effect in a system that previously responded. None of those symptoms identify their own cause, which is why mass balance and quantitative recovery, rather than peak purity alone, are the measurements that resolve them. Controlling the variable is more productive than predicting it.
What does the published SS-31 literature establish, and what does it not?
The published literature on this compound characterizes mechanism and bioactivity in laboratory models; it does not establish storage stability, and the distinction matters when evaluating claims. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury (J Am Soc Nephrol, 2011) reports effects on mitochondrial energetics and tissue injury in a rodent ischemia-reperfusion model. The 2013 cardiolipin study works in isolated mitochondria and ischemic tissue preparations. The 2004 JBC study works in cell culture and ex vivo preparations. The 2014 review synthesizes these into a cardiolipin-centred mechanistic account.
Each of those papers has the limits that come with its model system. Isolated mitochondria preparations remove the cellular context that governs uptake and local concentration. Rodent ischemia-reperfusion models are informative about mechanism and poorly predictive of human outcomes on their own. Cell-culture antioxidant assays measure radical chemistry under conditions chosen to make radical chemistry measurable. Clinical programs have studied elamipretide in mitochondrial disease, and those programs are outside the scope of a handling and stability brief; nothing in them substitutes for analytical data on a particular research lot.
What none of these papers supply is a degradation profile, a photostability dataset, a forced-degradation chromatogram or a solution hold time for the compound. That absence is not a criticism of the papers, which were not designed to answer those questions. It does mean that any stability statement about this peptide either comes from a laboratory's own analysis, from a supplier's lot documentation, or from general peptide chemistry reasoning of the kind set out above, and a reader is entitled to know which of the three is being offered. Real Peptides supplies the compound for research use and publishes lot certificates; the generalizations in this brief are chemistry, not measurements on a specific lot.
Does Real Peptides provide preparation or handling protocols for SS-31?
No. Real Peptides supplies research-use-only compounds and does not provide preparation, handling-for-use or application guidance of any kind, because these materials are sold for laboratory research and not for human consumption. What the company does publish is the documentation a laboratory needs to verify what it has received: independent third-party certificates of analysis for every batch at the COA library, catalog listings with CAS and molecular identity information such as the SS-31 (elamipretide) product page and the SS-31 compound overview, the full catalog at the shop, and location and shipping information at the location page.
The education that is appropriate on a page like this stops at the concentration framework, which is arithmetic rather than instruction. Concentration equals mass divided by volume. A stated mass of material taken into a stated volume of solvent defines a nominal concentration in milligrams per millilitre, and every downstream calculation inherits whatever error exists in that first figure. The sources of that error have already been described: gross salt mass versus net peptide content, residual water, and material lost to container surfaces.
Anything beyond that, including solvent selection, preparation steps, handling for use or any schedule, falls outside what a research-use-only supplier provides and outside what this brief covers. Researchers working with any peptide answer those questions from their institution's protocols, their own method development and the published methods sections of the literature relevant to their model system.
What does a practical stability assessment look like in a research laboratory?
A defensible stability assessment has four components: a baseline, controlled conditions, scheduled analysis by a stability-indicating method, and documentation. The baseline is established on receipt, by running the laboratory's own chromatographic and mass spectrometric methods on the lot and comparing the result against the supplier certificate, then retaining a reference portion at the coldest available storage condition so that every later comparison has an unchanged benchmark.
Controlled conditions mean that each test sample is held at one defined temperature, in one defined container type, with light exposure either excluded or deliberately applied, and with the number of warming events recorded rather than estimated. A sample whose history is unknown generates a result that cannot be attributed to any cause.
Scheduled analysis means time points chosen in advance rather than when a problem is suspected, with each point analyzed by a method that has been shown to separate the relevant degradants. That demonstration comes from forced degradation under the ICH Q1A(R2) framework: deliberately stressing portions of the material with acid, base, an oxidant, heat and light, then confirming that the resulting peaks resolve from the parent. The oxidative stress arm is the most informative for this peptide given the reactivity of its phenolic ring, and the photolytic arm, run against a protected control as ICH Q1B describes, answers the light question directly.
Documentation closes the loop. Lot number, certificate reference, storage temperature logs, thaw counts, chromatographic conditions, overlay traces and mass spectra together constitute a record that supports a claim about material integrity. Without that record, a laboratory reporting an unexpected result cannot distinguish a biological finding from a chemistry problem, and reviewers are increasingly unwilling to assume the former. For a compound whose reported activity depends on a specific and chemically reactive side chain, that distinction is not a formality.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004. PMID: 15178689. pubmed.ncbi.nlm.nih.gov/15178689
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165. pubmed.ncbi.nlm.nih.gov/24117165
- Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology. 2011. PMID: 21546574. pubmed.ncbi.nlm.nih.gov/21546574
- Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010. PMID: 20143256. pubmed.ncbi.nlm.nih.gov/20143256
- Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics. 1999. PMID: 10460913. pubmed.ncbi.nlm.nih.gov/10460913
- Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics. 2000. PMID: 10967427. pubmed.ncbi.nlm.nih.gov/10967427
- Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry. 1987. PMID: 3805008. pubmed.ncbi.nlm.nih.gov/3805008
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA